Synageva BioPharma (GEVA +0.9%) says the first patient has been initiated treatment in its Phase 3 study of sebelipase alfa in children and adults with late onset lysosomal acid lipase deficiency. Once fully initiated, the trial will enroll 50 child and adult patients with late onset LAL Deficiency.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs